The diverse modalities targeting B7-H3

ADCs against the target have raised safety concerns, but companies are hitting B7-H3 with other modalities

May 14, 2024 11:18 PM UTC

Safety concerns have emerged for vobramitamab duocarmazine, one of the leading antibody-drug conjugates against B7-H3, but those concerns may not be related to the target. A pipeline of diverse modalities against the cell surface receptor is developing behind two ADCs.

Last week, MacroGenics Inc. (NASDAQ:MGNX) reported five patient deaths in a Phase II prostate cancer study of vobramitamab duocarmazine (vobra duo), three of which are under investigation as potentially study drug related. Despite the toxicities, MacroGenics plans to advance the program to a Phase III study in the indication...